The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening

European Journal of Epidemiology

Volumn 32, Issue 6, 2017, Pages 495-500

  García Albéniz, Xabier ^a,b   Hsu, John ^b,c   Hernán, Miguel A ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Causal inference; Colon cancer screening; Target trial

Indexed keywords

ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; FOLLOW UP; HUMAN; INCIDENCE; MEDICARE; ORGANIZATION AND MANAGEMENT; COLORECTAL TUMOR; COMPARATIVE EFFECTIVENESS; EARLY CANCER DIAGNOSIS; MASS SCREENING; OBSERVATIONAL STUDY; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES;

COLORECTAL NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; EARLY DETECTION OF CANCER; HUMANS; MASS SCREENING; MEDICARE; OBSERVATIONAL STUDIES AS TOPIC; UNITED STATES;

EID: 85026895187     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-017-0287-2     Document Type: Article

References (13)

1. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.
2. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016;315:2564–75.
3. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.
4. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami H-O, van Ballegooijen M, et al. The NordICC study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012;44:695–702.
5. Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) [Internet]. [cited 2015 Jun 3]. https://clinicaltrials.gov/ct2/show/NCT01239082.
6. Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016;66:96–114.
7. García-Albéniz X, Hsu J, Bretthauer M, Hernán MA. Effectiveness of screening colonoscopy to prevent colorectal cancer among medicare beneficiaries aged 70 to 79 years. Ann Intern Med. 2017;166:18.
8. Stock D, Paszat LF, Rabeneck L. Colorectal cancer mortality reduction is associated with having at least 1 colonoscopy within the previous 10 years among a population-wide cohort of screening age. Gastrointest Endosc. 2016;84:133–41.
9. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615–25.
10. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5.
11. Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766–79.
12. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2011;61:1036–40.
13. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med. 1993;328:1365–71.